Biologics - Resources

22/04/24 - Earth Day marks a moment to reflect on the planet's health and our collective efforts to nurture it. To celebrate Earth Day, this article will examine the strides the pharmaceutical and biotechnology industry has made towards fostering sustainable and green practices alongside the challenges.

Content Type

Subjects

Keywords

Peptides

Sustainable Pharma: Celebrating Progress and Confronting Challenges on Earth Day

Earth Day marks a moment to reflect on the planet's health and our collective efforts to nurture it. To celebrate Earth Day, this article will examine the strides the pharmaceutical and biotechnology industry has made towards fostering sustainable and green practices alongside the challenges.

Proteins & Antibodies

Rapid Analytical Approach for Biologics Characterization Using Mass Photometry

On-demand webinar featuring Dr Racha Majed, Technical Sales Specialist, Refeyn

Bispecifics

Merus's Preclinical Bispecific Zeno Demonstrates Efficacy in Cancer Models

Zeno interrupts the dimerization of HER2 and HER3 and prevents NRG1/HER3 tumour signalling.

Oligonucleotides

Japanese Team Successfully Skip Abnormal Gene In Vitro With Antisense Oligonucleotide for BPAN

Rare disease BPAN currently has no treatment options, this new research investigates whether antisense oligonucleotide therapies could be the answer to address this unmet need.

Oligonucleotides

Oligo Sequencing Technologies - What Methods and Techniques Are Utilized in the Pharmaceutical Industry?

Oligo sequencing revolutionizes biologics research, ensuring accurate analysis of oligonucleotides. Biologics by Oxford Global explores methods, safety, sustainability, and future trends. Despite challenges, advancements promise exciting opportunities for scientific discovery.

Oligonucleotides

Innovation at the Crossroads: Oligonucleotide Therapeutics and the Evolution of Drug Design

Can oligonucleotide therapeutics shape the future of healthcare? We journey through AI frontiers, sustainable synthesis, and regulatory challenges.

eBook: Sustainability & Green Innovations in Pharma and Healthcare

Read how innovators are transforming the industry towards one that prioritizes both healthy patients and a healthy planet.

Peptides

Recombinant vs. Chemical Peptide Synthesis: A Question of Sustainability

Recombinant and chemical peptide synthesis methods both have use cases in modern peptide production. Today the industry is looking to sustainable approaches to both.

Peptides

The Vital Role of Sustainable Peptide Synthesis in Advancing Drug Development

Sustainable peptide synthesis refers to the development and implementation of methods that minimize the environmental impact of peptide manufacturing while maintaining high efficiency and yield.

Peptides

Mechanochemical Synthesis as a Solvent-Free Peptide Synthesis Method

Mechanochemical synthesis could unlock new pathways for obtaining peptides in a sustainable and ecologically friendly way.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.

Oligonucleotides

Sustainability in Pharmaceutical Manufacture and Healthcare Provision

How do things stand with sustainability in pharmaceutical manufacture at present? What are some members of the industry doing to reduce their carbon footprint?

Peptides

New peptide with hope of treating triple-negative breast cancer

The preclinical peptide could unlock much needed treatment options for patients with triple-negative breast cancer.

Biologics Analysis

Overcoming the Hurdles: Navigating the Challenges of Bioconjugate Development

Bioconjugate development, exemplified by ADCs such as T-DM1 and Mylotarg, tackles issues like stability and specificity, benefiting from innovative solutions and services to enhance therapeutic precision in biologics.

Oligonucleotides

New Approach to Oligo-Peptide Synthesis from Novo and Aarhus University

The collaboration could unlock the more cost-effective synthesis of oligonucleotide-peptide conjugates.

Proteins & Antibodies

The Current Landscape of ADC Approvals and Market Trends: Q&A With Mahendra Deonarain, CEO of Antikor Biopharma

While a recent spike in ADC approvals may not last forever, Antikor Biopharma’s Mahendra Deonarain asserts that antibody-drug conjugates are here to stay.

Proteins & Antibodies

Introducing the Development and Clinical Landscape of Bi and Multispecific Antibodies

While bispecific antibodies target two specific entities, multispecific antibodies can target more than two. The use of these engineered antibodies offers the potential for enhanced therapeutic strategies by simultaneously addressing multiple aspects of a disease.

Proteins & Antibodies

Cytokines and Immunocytokines in Therapeutic Approaches

Advancements in cytokine understanding and synthetic immunology enable precise immune modulation, particularly in cancer treatment. However, challenges like short half-lives and side effects impact their wider clinical application.

Proteins & Antibodies

Post-Event Proceedings - Biologics 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Biologics 2023

Vaccines

Uncovering the Latest Trends in Vaccine Development and Technology: Advances in Biotechnology and Vaccines

Proteins & Antibodies

Multispecific Antibody Development: Interview with Yue Liu, President and Founder of Ab Therapeutics

Discussing using a computational drug discovery platform for the development of multispecific antibody therapeutics.

Vaccines

Strengthening Preparedness for the Next Pandemic: Interview with Ramin Sabet-Azad, CMC Lead, CEPI

How do we prepare for the next pandemic?

Proteins & Antibodies

Handbook for Stem Cell Research

This whitepaper by Sino Biological discusses the different types of stem cells based on their origin and potential, as well as the factors that direct their differentiation toward specific lineages or cell types.

Vaccines

Vaccine Production for Better Global Access

How were the COVID-19 vaccines developed so fast? And why were some countries left behind?

Vaccines

Pioneers of COVID-19 mRNA Vaccine Win Nobel Prize

Professors Katalin Karikó and Drew Weissman have been awarded the 2023 Nobel Prize in Medicine for their contributions to the development of the COVID-19 mRNA vaccine.

Proteins & Antibodies

FDA Approves Takeda’s Subcutaneous Ulcerative Colitis mAb

The company can now sell their biologic for ulcerative colitis in a subcutaneous form on the US market.

Proteins & Antibodies

Navigating the Pharma R&D Regulatory Landscape 2023

Our ‘Navigating the Regulatory Landscape’ eBook has been designed to provide you with invaluable insights into the intricacies of regulations & policies surrounding the challenges and opportunities of Real-World Data, genome editing, biomedical informatics, manufacturing and many more.

Oligonucleotides

How Do Regulatory Considerations Impact the Clinical Development of Oligonucleotide Therapies?

What are the regulatory considerations that need to be made in the clinic for oligonucleotide therapies? What's the existing guidance for this emerging modality?

Peptides

Trends and Challenges in Peptide Bioanalysis and Production

Here, we investigate some of the main trends and challenges in peptide bioanalysis such as non-specific binding, and look at how they can be circumvented.

Oligonucleotides

Revolutionizing Biologics: Unveiling the Challenges and Innovations in Large-Scale Oligonucleotide Synthesis

Proteins & Antibodies

Amgen and Synaffix Pen $2 Billion

Amgen and Synaffix's partnership aims to revolutionise cancer treatment by developing highly targeted antibody-drug conjugates (ADCs).

Oligonucleotides

Assessment of Long IVT mRNA Fragments with the Aligent Fragment Analyzer Systems

Oligonucleotides

Early Formulation Screening with Merck

Oligonucleotides

Early-Stage Development of LNP Formulations

Oligonucleotides

Friedrich Miescher: The Pioneer of Nucleic Acid Discovery

As medical research that is founded on nucleic acids continues to progress, we take a step back to look at the man who first discovered nucleic acids.

Proteins & Antibodies

F-star and Takeda Collaborate to Pave the Way for Next-Generation Cancer Therapies

F-star Therapeutics and Takeda are partnering to develop next-generation multi-specific antibodies for cancer immunotherapy, building on F-star's advanced platforms.

Oligonucleotides

GMP Manufacturing of LNP Formulations

Oligonucleotides

Lipids for Pharmaceutical Applications

Oligonucleotides

mRNA CDMO Services to Accelerate your mRNA Program

Oligonucleotides

Oligonucleotide Purification Solutions

Vaccines

Personalised Cancer Vaccines: Tailored Immunotherapy for Precision Treatment

We take a look at what personalised cancer vaccines are, how they are developed, and how they are changing the field of immunotherapy.

Oligonucleotides

Rapid Analysis of mRNA 5' Capping

Oligonucleotides

Solid Phase Oligonucleotide Synthesis

Oligonucleotides

The Growing Potential for Antisense Oligonucleotide Therapy

Antisense oligonucleotides hold major promise in future patient treatment approaches. Through targeting RNA to regulate protein expression, they can help to address diseases at their source and advance therapeutic outcomes.

Biologics Analysis

Biologics Market Trends and Predictions: New Horizons Beckon

Here, we outline some of the main trends anticipated in market growth and development for biologics in the next few years. The global biologics market is predicted to exceed $600bn by 2032, driven by demand for personalised treatments for chronic diseases.

Oligonucleotides

Targeted Delivery with FORCE: Novel Approaches in Oligo Therapeutics

How are oligo therapeutics revolutionising genetic disease treatments through precise targeting and transformative therapies? In this article, we explore how they provide precise gene expression interference for untreatable conditions by directly targeting disease-associated proteins and genetic mutations.

Vaccines

How Will Commercialisation Impact COVID-19 Vaccine Prices in the US?

We take a look at how the commercialisation of COVID-19 vaccines in the US will impact the price of the vital therapeutic.

Bispecifics

WuXi Biologics and GSK Enter License Agreement for Bispecific Development

The Pharma giants have partnered to advance the development of bispecific T cell engaging antibodies using WuXi’s platforms.

Bispecifics

T Cell Engagement and Activation: New Developments

As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape.

Proteins & Antibodies

Accelerating time to market through process innovation

On-Demand Workshop presented by Andreas Castan, Strategic Technologies Director at Cytiva, Cauroline Hausner, Business Development Manager, Aseptic Filling at Cytiva, Ola Tuvesson, Chief Technology Officer at NorthX Biologics & Sofie Östemar, Product Manager, Connected & Continuous at Cytiva

Proteins & Antibodies

Xentria and Meitheal Collaborate on Breakthrough Lung Disease Treatment

Xentria and Meitheal partner to develop a breakthrough drug for pulmonary sarcoidosis, aiming to improve patient outcomes.

Proteins & Antibodies

Revolutionising Antibody Engineering: The Groundbreaking Work of Sir Gregory Winter

We take a look at the work of Sir Gregory Winter, and how it has changed the landscape of therapeutic antibody production.

Oligonucleotides

Transforming Oligonucleotide Manufacturing: A Transformative UK Collaboration

A new collaboration from the Medicines Manufacturing Innovation Centre is looking to change the face of oligonucleotide development.

Proteins & Antibodies

Unravelling the Link Between Type 2 Diabetes and Proteins

In honour of this week marking Type 2 Diabetes Prevention Week, we take a look at the intricate link between the disease and proteins.

Peptides

The Power of Collaboration: How The Sustainable Healthcare Coalition Measures the Impact of Sustainable Healthcare

The Sustainable Healthcare Coalition (SHC) emphasises the importance of collaboration with industry to address climate change in healthcare.

Proteins & Antibodies

Sony and Astellas Team Up to Create Breakthrough ADC Oncology Platform

Sony and Astellas join forces to develop an ADC platform that leverages Sony's Kiravia Backbone for enhanced drug delivery and stability.

Peptides

Sustainable Medicines Partnership: A Pan Stakeholder Action Collaborative

A program to reduce the waste of medicines and waste from medicines, centred around six pillars for sustainable pharma.

Oligonucleotides

Refractive Index Paves the Way to Greener Peptide and Oligonucleotide Synthesis

John Lopez of Novartis discusses the more sustainable possibilities refractive index monitoring offers in SPPS and SPOS.

Peptides

Peptide Characterisation Methods and Impurity Detection

Key opinion leaders discuss techniques for peptide characterisation and the challenges posed by increasing regulatory requirements.

Peptides

Insulin: Recombinant Production, Sustainability, and Chemistry

Novo Nordisk has implemented recombinant peptide production techniques with chemical and enzymatic transformations to reduce its carbon footprint in insulin production, as explained by Thomas Høeg-Jensen, Scientific Director at Novo Nordisk.

Vaccines

World Malaria Day 2023: Breakthroughs in Malaria Vaccinations

April 25th marks World Malaria Day, an opportunity to raise awareness about the disease’s impact and efforts to control and prevent it.

Proteins & Antibodies

App Note: CAR-T: A Promising Cell Therapy for Cancer Treatment

This application note by Sino Biological explores the key steps involved in CAR-T production to provide insights into the challenges that may impede successful CAR-T therapy.

Bispecifics

The Bispecific Antibody Landscape

Key opinion leaders explore recent developments for bispecific antibodies, from new delivery technologies to the complexity of their pharmacokinetic profiles.

Proteins & Antibodies

Tiny but Mighty Molecular Syringe Developed Using AI

An AI-modified molecular “syringe” harnessed from bacteria could revolutionise protein delivery for gene and cancer therapies.

Vaccines

In Vivo Model Design and Assay Selection to Aid in Progression from Preclinical to Clinical

Nexelis discussed the preclinical stage of vaccine development at Vaccines EU 2022, highlighting that the choices made during this stage will impact the rest of the development process.

Proteins & Antibodies

Absolute Biotech: Cancer Research Reagents

Proteins & Antibodies

Absolute Biotech: Recombinant Antibody Services

Biologics Analysis

ATUM: Leap-in Transposases

Peptides

Bachem: The PEC Platform

Biologics Analysis

Bio-Works: WorkBeads IMAC Resins

Biologics Analysis

Bio-Works: WorkBeads Ion Exchange Resins

Biologics Analysis

Bio-Works: WorkBeads Size Exclusion Resins

Biologics Analysis

FOx Biosystems: Versatile and Fast IgG Screening

Biologics Analysis

Unchained Labs: HoneybUN

Biologics Analysis

Unchained Labs: StUNner

Oligonucleotides

Agilent: Oligonucleotide Purification Solutions

Vaccines

Carterra: High-Throughput SPR Technology

Biologics Analysis

Twist Bioscience: Advanced DNA Tools for Engineering Better Chimeric Antigen Receptors

Biologics Analysis

Twist Bioscience: Clonal Genes

Biologics Analysis

Twist Bioscience: Library of Libraries

Oligonucleotides

Twist Bioscience: Oligo Pools

Biologics Analysis

Unchained Labs: UNcle

Biosimilars & Biobetters

FDA's AI Model Enhances Safety of Biosimilar Therapeutic Proteins

Thanks to the FDA's new AI-powered imaging tool, the safety profile of newly developed biosimilar therapeutic protiens may improve.

Proteins & Antibodies

Interview with Andrew Brown, Head of Process Development Sciences at Lonza

Andrew Brown, Head of Process Development Sciences at Lonza, talks about Lonza's approach to process development.

Peptides

AI-Discovered Peptide has Dramatic Impact on Muscle Conditioning

Are plant-derived peptides set to replace animal proteins as the go-to supplement for muscle conditioning?

Oligonucleotides

The Complex Case of Antisense Oligonucleotides

We gain a glimpse into what the landscape of antisense oligonucleotides looks like today, from computational representations to protein purification.

Vaccines

MIT Team Create AI-Generated Universal COVID Vaccine

New COVID variants are still a significant risk; but could an AI-generated universal COVID vaccine be the key to overcoming this?

Proteins & Antibodies

How AI is Changing the Game for Protein Design

Researchers at the University of Washington have succeeded in using machine learning to synthesise artificial enzymes which are actually functional in cells.

Proteins & Antibodies

Computational Tools and AI/ML for Antibody Engineering

Opinion leaders from Merck and AbbVie discuss how antibody-based molecular engineering is developing with new AI/ML technologies.

Biosimilars & Biobetters

Biocon’s Biosimilar Difficulties: Successive FDA Rejections Don’t Inspire Hope

Biocon suffer another FDA rejection due to data and manufacturing concerns, this time for their bevacizumab biosimilar.

Vaccines

The EMA’s Vaccines Working Party: The New Authority on Vaccines

The Vaccines Working Party was established last year by the EMA, but what are its main tasks, and how are they looking to achieve them?

Proteins & Antibodies

POLIVY vs ODAC: Can the Cancer Drug Score Another Indication?

The Oncologic Drugs Advisory Committee are preparing to weigh in on whether the FDA should grant another indication for Roche’s POLIVY.

Proteins & Antibodies

No More Hold-Ups: FDA Lifts Hold on Parkinson’s Drug

The FDA has repealed the hold placed on clinical trials for the Parkinson’s drug IkT-148009, which began in November.

Vaccines

The Race for an RSV Vaccine Approval

Things are heating up in the race to pinch the first FDA approval of an RSV vaccine, as Moderna joins Pfizer and GSK in the running.

Proteins & Antibodies

FDA Grant Approval for Alzheimer's Drug Leqembi

The US regulators have approved Eisai and Biogen’s Alzheimer’s drug, lecanemab, a “landmark” moment for the disease.

Peptides

The Future of Peptide Chemistry and Sustainability

The peptide market is continually developing, but how are manufacturers responding to its new requirements and altering the landscape of peptide manufacturing?

Bispecifics

Regeneron’s New Bispecific: A Toxic Success?

Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.

Vaccines

Dual-Action Malaria Vaccine Takes the Punch out of the Parasite

A new vaccine duo developed by scientists at George Washington University stops malaria infection and transmission, the double attack needed to eradicate the disease.

Vaccines

Nexelis’s Collaborative Development for Optimal Clinical Assay

November’s webinar, Adaptive Laboratory Environment: Collaboration Across our Development Teams Produces Optimal Clinical Assay, discusses Nexelis’s process in recombinant protein production, optimisation, and characterisation.

Vaccines

Overcoming Vaccine Manufacturing Challenges

Experts from King’s College London, Janssen, and Merck Sharp & Dohme congregate to talk the future of optimised vaccine manufacturing.

Vaccines

Vaccines After COVID: How the Pandemic Has Changed the Vaccination Market

During the pandemic, a layperson couldn't avoid learning about vaccinations. But as the world returns to “normal”, how does this new-found focus on vaccines manifest for regulators, producers, prescribers, and the public?

Vaccines

Vaccines Europe: Presentations You Won’t Want to Miss

Find out about some of Oxford Global’s most highly anticipated presentations happening at our upcoming Vaccines Congress.

Proteins & Antibodies

Roche Fail to Follow in Eisai’s Footsteps: Alzheimer’s Drug Flunks Phase III Trials

Roche revealed that they will stop all Alzheimer’s trials after anti-amyloid beta antibody gantenerumab fails Phase III trials.

Proteins & Antibodies

Heart-to-Heart or Head-to-Head: Amgen Heart Drug to Challenge Novartis

New data released from Amgen’s phase II study of olpasiran suggests that the drug could fill a niche in the cardiovascular market.

Vaccines

Universal Vaccines & Vaccine Therapeutics

Mark Doherty, Senior Medical Manager at GSK, leads a Discussion Group on leveraging the mechanisms of action in therapeutic vaccine development.

Proteins & Antibodies

AbbVie Ditch Phase II Autoimmune Drug

AbbVie announced that they are dropping the ROR? inverse agonist, marking the end of their collaboration with Inventiva

Bispecifics

Exploring & Developing Various Biotherapeutic Modalities

Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.

Vaccines

3-Dose Hepatitis B Vaccine Offers Full Protection for People with HIV

Phase III clinical trials from the University of Cincinnati have shown seroprotection in 100% of HIV-positive participants after a 3-dose regimen of the HEPLISAV-B vaccine.

Biologics Analysis

Mass Spectrometry: Shortening Time Scales and Progressing Towards Automation

Discover the top bioanalysis presentations from Biologics UK 2022.

Proteins & Antibodies

Oxford Global's R&D Key 40 Stories 2022

Download a copy of the R&D Key 40 Stories 2022 eBook today.

Bispecifics

Gilead Pay Big Bucks for MacroGenics' Blood-Cancer Targeting Bispecific

Gilead announced a $1.7 billion licence-option deal for MacroGenics’ MGD024 bispecific once Phase I trials conclude.

Biologics Analysis

Turbocharging Potency Assays – Challenges and Opportunities from Multispecific Drug Modalities

The development of multispecific drugs is an inherently complex and challenging process. Barbara Hebeis of AstraZeneca talks us through challenges surrounding the development of appropriate potency assays, and the opportunities the field offers.

Proteins & Antibodies

The STING in Immunotherapy’s Tail

Research from the University of North Carolina into STING agonists provides new insights for immunotherapy cancer treatments.

Proteins & Antibodies

Eisai’s Alzheimer's Drug Offers New Hope

Eisai’s new drug lecanemab has shown small but significant benefits for people with early Alzheimer’s disease.

Proteins & Antibodies

Is Your WASH Causing Inflammation? Protein Complex Linked to Inflammatory Conditions

Research published by the Scripps Research Institute reveals the WASH protein complex as a crucial factor in neutrophil-triggered inflammation.

Vaccines

Why We Develop Autoimmunity: Hyperstimulation of Genetically Prone Subjects

Professor Yehuda Shoenfeld explains his findings in establishing links between genetic predisposition and hyperstimulation of the immune system and how this may help us better understand the development of autoimmunity.

Vaccines

Advanced Vaccine Platforms & Technologies

Wieslaw Swietnicki, Head of Biosynthesis and Bioengineering Group at the Institute of Industrial Organic Chemistry, leads a discussion on the current outlook for advanced vaccine platforms, technologies, and development.

Vaccines

Pfizer’s Pneumococcal Vaccine Shows Great Promise in European Study

Pfizer’s new PCV candidate is set to become the most effective protector against pneumococcal infections for infants.

Peptides

FDA Gives Green Light to Long-Awaited Botox Competitor

Competition between cosmetic treatments begins.

Oligonucleotides

Sciex Molecular Profiler Software

Oligonucleotides

Sciex Zeno Trap

Biosimilars & Biobetters

Retinal Disease Drug Receives Approval from European Commission

Ranivisio is a biosimilar of Lucentis which treats serious retinal diseases.

Vaccines

Using Humanised Mice to Evaluate Vaccine Efficacy

Kymab Ltd presents the utility of mice models for studying human immune response to complex vaccines.

Vaccines

Moderna Sues Pfizer and BioNTech over mRNA COVID-19 Vaccines

Why is Moderna suing Pfizer and BioNTech over its COVID-19 vaccine despite recent pledge?

Vaccines

mRNA Therapeutics: Learning from Preclinical Concepts to Ensure Clinical Translatability in Nanomedicinal Approaches

This Commentary article explores the applications of mRNA therapeutics in disease treatment and prevention. The commercial presence of microfluidics technologies has improved process development, and has helped to provide rapid development along with the existence of established formulation principles for vaccines.

Vaccines

Q & A with Vincent Dewar

We interview Vincent Dewar, Associate Director and Head of Immunoassay Analytical Research Development at GlaxoSmithKline, to learn more about the importance of immunoassays for vaccine development.

Biologics Analysis

The Black Box Effect - How Can AI and ML Provide Transparent Insights for Drug Discovery?

We interview Martin Akerman, Chief Technology Officer and Co-Founder at Envisagenics to find out about machine learning for drug target discovery in RNA.

Biologics Analysis

Nature Announces Top 10 R&D Institutes

The 2021 report is in, but who made the cut?

Peptides

Migraine Drug Doubles its Sales, Despite Expansion Setback

Vyepti is the first intravenous medication approved for migraine treatment.

Vaccines

Will Vaccine Manufacturers go into Overdrive this Flu Season?

With influenza expected to make a return this winter, vaccine manufacturers may be facing more demand than usual.

Vaccines

Children in London to be Given Urgent Polio Booster Vaccine

Children between one and nine years old to be given polio jab to curb the spread of the virus throughout the city.

Vaccines

China Warns of New Virus Transmitted by Shrews

How worrying is the new ‘Langya’ virus spreading in China?

Vaccines

Monkeypox Cases in UK Begin to Plateau

Statistics show that the number of people infected with the monkeypox virus is starting to slow down.

Proteins & Antibodies

AstraZeneca Suffers Sales Decline for COVID Med Evusheld

A 24 million loss has been reported for the preventative COVID-19 treatment.

Proteins & Antibodies

Market Battle for Rare Disease Treatment

Argenx and AstraZeneca are set to become market rivals in their general myasthenia gravis (gMG) treatments, analysts claim.

Bispecifics

Bispecific Antibodies for Solid Tumours

Laura von Schantz, Vice President of Discovery at Alligator Bioscience, leads a discussion on the current and future opportunities of bispecific antibodies for solid tumour treatment.

Vaccines

European Approval for Monkeypox Vaccine

The European Commission (EC) has approved Bavarian Nordic’s Imvanex vaccine which protects against monkeypox, and diseases caused by the vaccinia virus.

Vaccines

Discussion Group Announcement

Oxford Global’s next round of Biologics Discussion Groups announced.

Proteins & Antibodies

Widening the Therapeutic Window: Development of Antibody Drug Conjugates for Solid Tumours

Compared to non-solid tumours, solid tumours are more difficult to treat with conventional therapeutic methods. Antibody drug conjugates – biopharmaceutical drugs designed as a targeted therapy for treating cancer – represent a viable treatment alternative.

Proteins & Antibodies

Novartis Withdraws Tislelizumab Submission

Novartis scraps US submission of tislelizumab as a monotherapy for non-small cell lung cancer.

Vaccines

New Speakers Announced: Vaccines Europe Congress 2022

Exciting updates revealed about upcoming Vaccines Europe: In-Person congress happening 29-30 November 2022.

Proteins & Antibodies

Blood Test Predicts Presence of Beta-Amyloid in Brain

A study by the National Institute of Ageing found that a new blood test can accurately predict the presence of beta-amyloid plaques in the brain.

Vaccines

US Doubles its Supply of Monkeypox Vaccines

The US government has more than doubled its supply of Monkeypox vaccines amidst rising fears.

Bispecifics

AstraZeneca Buys T Cell Engager for $100 Million

Pharma giant makes a major investment in improving the standards of care in B cell malignancies.

Proteins & Antibodies

Recommended Approval for AbbVie’s Rinvoq Treatment

AbbVie announces official recommended approval of it Rinvoq treatment for adults with active non-radiographic axial spondyloarthritis.

Biologics Analysis

The Countdown Begins: How ADCs will Become the Next Generation of Biologics Therapeutics

Key opinion leaders from AbbVie, Ambrx Inc, and Antikor Biopharma talk about the cutting-edge technology’s promise for better therapeutic index.

Bispecifics

Why Drug Delivery is Key to New Drug Discovery

Method of delivery is just as important as discovering new medicines.

Vaccines

Q & A with Derek O'Hagan

We interview Derek O'Hagan, Senior Advisor at GlaxoSmithKline Vaccines to learn more about the future of the vaccine.

Vaccines

Polio Resurgence Hits UK

The poliovirus is on the rise for the first time in nearly 40 years.

Vaccines

Most Anticipated Presentations: Vaccines Europe

Discover key event highlights from Oxford Global's upcoming Vaccines Congress 2022.

Peptides

Oral Delivery of Peptides

Nazneen Dewji, President and CEO of Cenna Biosciences leads a discussion on the strategies to overcome the challenges ‘Oral Delivery of Peptides’.

Proteins & Antibodies

Top 3 Biologics News Headlines

Hot off the press, we look at this week’s breaking news stories from the Biologics industry.

Proteins & Antibodies

Delays for New COVID Drugs

Clinical studies testing treatments for severe COVID-19 face major delays due to eligibility issues.

Proteins & Antibodies

Bispecific CAR-T Cell Therapies: Successful Applications in Mouse Tumour Models

Two roadblocks to the successful application of treatments for tumourous tissues are heterogenous antigen expression and antigen loss. Bispecific CAR-T cells, capable of simultaneously binding to two different antigens via heavy chain-only domains, may present a solution.

Vaccines

FDA Approves GSK’s MMR Vaccine

The FDA gives the green light to GSK’s measles, mumps, and rubella vaccine, providing US clinicians with a new treatment option for childhood inoculation for first time in more than 50 years.

Bispecifics

Broadening Horizons for Bispecific Effector Cell Redirection

Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.

Proteins & Antibodies

Study Shows ML Optimises Therapeutic Antibodies

Researchers from ETH Zurich demonstrate the promise of deep learning for predicting antigen specificity.

Peptides

Peptide Production: Biopharmaceutical Manufacturing of Next Generation Peptides

In this Commentary article, we explore how innovative technologies like expression tags could help to overcome challenges associated with recombinant peptide production. The potential for recombinant production to slash manufacturing costs has made it a focal area of research for companies such as Boehringer Ingelheim.

Peptides

Peptide Discovery: Unlocking the Future of Disruptive Therapeutics

UCB, Bicycle Therapeutics, and Sanofi share their latest findings in Peptide discovery at Biologics UK 2022.

Proteins & Antibodies

Advanced Antibody Engineering: AI, ML, and Computational Tools

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘Accelerating Antibody Engineering With AI/ML & Advanced Computational Tools and Technologies’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

Proteins & Antibodies

What’s Next for Antibody-Based Therapeutic Discovery and Optimisation?

As market leaders in the biologics field, there is no sign of demand for antibody-based therapies slowing down any time soon. With exclusive insights from the CRUK-AstraZeneca Antibody Alliance Laboratory, we look towards the future of antibody discovery and optimisation.

Peptides

Symphony® X

Oligonucleotides

Sustainable Synthesis of Therapeutic Oligonucleotides

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Sustainable Synthesis of Therapeutic Oligonucleotides’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

Proteins & Antibodies

Sane in the Membrane: Salipro One-Step Reconstitution of GPCRs and Ion Channels

While membrane proteins are inherently unstable and challenging to work with, Salipro Biotech are focusing on the stabilisation of challenging protein targets for a variety of downstream applications. This Commentary article explores how Salipro’s platform technology enables new opportunities for drug development.

Proteins & Antibodies

Advanced DNA Tools for Engineering Better Chimeric Antigen Receptors

Proteins & Antibodies

AmMagTM SA Plus Automated Protein Purification System

Proteins & Antibodies

AN2 Sensitive Protein Quantification in Whole Blood

Biologics Analysis

Analytical Support for Biologics

Proteins & Antibodies

Bachem: In Vitro Diagnostic Peptides

Proteins & Antibodies

Bionamic Platform Introduction

Vaccines

BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies

Vaccines

BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants

Proteins & Antibodies

Bio-Techne Product Portfolio Overview

Proteins & Antibodies

Bio-Techne: Genome Engineering for Cell Therapy Manufacturing

Proteins & Antibodies

Bio-Techne: Maurice

Proteins & Antibodies

Bio-Techne's Custom Reagents and Contract Services

Proteins & Antibodies

Bio-Techne's Ella: Your Immunoassay Problem Solver

Proteins & Antibodies

Bio-Techne's Jess: Your Complete Protein Analysis Solution

Proteins & Antibodies

Extracellular Vesicle Quantification in Complex Matrices

Peptides

GL Biochem: Peptide Catalogue

Peptides

GL Biochem: The One-Stop Shop for Peptides

Proteins & Antibodies

High Sensitivity Assay Development on the LSA®

Proteins & Antibodies

High Throughput Gene-to-Antibody Production Services

Proteins & Antibodies

High Throughput SPR Kinetics

Proteins & Antibodies

Hyperimmune Library

Proteins & Antibodies

InstaDeep Promoted to NVIDIA Elite Service Delivery Partner

Proteins & Antibodies

Label-Free Protein Quantification in Bioproduction Samples

Proteins & Antibodies

Monitoring Immune Response to SARS-CoV-2

Proteins & Antibodies

NiHC200M Biosensor Kinetic Assays on the Carterra® LSA®

Proteins & Antibodies

PSILO® - Protein Structure Database and Visualization System

Proteins & Antibodies

Sensitive Protein Quantification in Crude Serum Samples: Comparison of FO-SPR and ELISA

Proteins & Antibodies

Solutions for the Whole Life Sciences Laboratory

Proteins & Antibodies

Speeding up T-Cell Receptor Discovery for Adoptive Cell Therapy

Proteins & Antibodies

Twist AI Hypermutated scFv Library

Proteins & Antibodies

Twist Ancestral scFv Library

Proteins & Antibodies

Twist Carbohydrate scFv Library

Proteins & Antibodies

Twist Combinatorial Assembly

Proteins & Antibodies

Twist Ion Channel scFv Library

Proteins & Antibodies

Twist Minotaur scFv Library

Proteins & Antibodies

Twist Structural scFv Library

Peptides

Vapourtec: Automated CF-SPPS and Evaluation of GLP-1 Peptide

Biologics Analysis

White POx Product Brochure

Proteins & Antibodies

ABclonal Molecular Biology Reagents

Proteins & Antibodies

ABclonal Product Introduction

Proteins & Antibodies

Ablexis and AlivaMab Discovery Services

Biologics Analysis

Almac Group: Analytical Services Brochure

Proteins & Antibodies

AmMag Protein A Magnetic Beads for Rapid Antibody Purification

Biologics Analysis

Benchling Life Sciences R&D Cloud

Proteins & Antibodies

Biologics by Design

Proteins & Antibodies

Biologics... Changing Treatment, Saving Lives

Biosimilars & Biobetters

Biosimilar Structural Comparison of Commercially Sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly Predict Activity for Use in an ELISA Product

Biologics Analysis

Biotage® PhyPrep

Proteins & Antibodies

Bio-Techne: Bioprocess Workflow Solutions

Peptides

Cleveing Peptides in Flow

Proteins & Antibodies

Custom Services of ABclonal

Proteins & Antibodies

Detecting Partial Unfolding of Hen Egg White Lysozyme in 2 M Guanidine Hydrochloride Solution using Microfluidic Modulation Spectroscopy (MMS)

Peptides

GL Biochem: Reagent Catalogue

Vaccines

InstaDeep Raises $100M to Scale Decision-Making AI Products that Solve Real-World Problems

Proteins & Antibodies

Introduction of ABclonal Molecular Enzyme Products

Proteins & Antibodies

Microfluidic Modulation Spectroscopy as a Non-Destructive Structural Characterisation Technique

Proteins & Antibodies

MOE - The Integrated Computational Platform

Proteins & Antibodies

Multi-Parameter Epitope-Centric Data Used to Elucidate Mechanisms of Action of Antibodies

Peptides

PurePep Chorus

Proteins & Antibodies

SARS-CoV-2 Research Reagents

Proteins & Antibodies

Secondary Structure Analysis of NIST Monoclonal Antibody Reference Material 8671 by Microfluidic Modulation Spectroscopy

Peptides

Secondary Structure Determination using MicrofluidicModulation Spectroscopy in the Presence of DMS

Biologics Analysis

The Biotage® PhyPrep Maxi Mega Giga

Proteins & Antibodies

The Molecular Operating Environment: Biologics Design and Protein Engineering

Biologics Analysis

xMAP Catalogue 2022

Biologics Analysis

xMAP INTELLIFLEX Systems

Proteins & Antibodies

T Cell Engagement and Redirection – Strategies, Methods, and T Cell Design

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group addressing ‘T Cell Engagement and Redirection – Strategies, Methods, and T Cell Design’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Oligonucleotides

Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine

With efficacy, safety, and targetability being the top three challenges facing the nucleotide-based therapeutic industry today, will oligo-based therapies fulfil their potential as a clinical modality?

Oligonucleotides

Oligonucleotide Chemistry & Therapeutics Symposium: Market Trends and Industry Challenges

The first of its kind, the Oligonucleotides: Chemistry & Therapeutics Symposium was a hit. We sat down with an advisory group of leading industry experts to hear their thoughts on the future of the Oligonucleotide drug industry as well as some of its key market trends and challenges.

Oligonucleotides

Characterisation of Therapeutic Oligonucleotides in Early Drug Discovery

Oligonucleotides are fast becoming a globally recognised form of therapeutic treatment. But how easy is it to analyse them? Director of AstraZeneca, Tomas Leek takes us through the analytic challenges of the early-stage oligonucleotide characterisation.

Bispecifics

Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment

Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies?

Peptides

Peptides Green Chemistry Strategies and Methods

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our January Discussion Group addressing ‘Peptides Green Chemistry Strategies and Methods’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Bispecifics

Bispecific and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Bi-and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Bispecifics

A New Cancer-Killing Bispecific Antibody Working Toward the Clinic in 2022

The joint development project by Alligator Bioscience and Aptevo Therapeutics, ALG.APV-527, shows potential in targeting solid tumours

Peptides

Advancing Peptide Therapeutics and Personalised Cancer Vaccines

In this Insight Article, we explore the future possibilities, challenges, and solutions in peptide purification and the delivery of precision medicine for immunotherapy.

Peptides

Peptides Congress: Market Trends and Industry Challenges

What are the key market trends and challenges facing the Peptides therapeutic industry today? We sat down with an advisory group of leading pharmaceutical and academic experts to discuss our latest Peptides Congress and the interesting insights it disclosed.

Peptides

Diabetology’s Oral Insulin Has Success in IIb Clinical Trial

Strides made in a landmark phase IIb oral insulin clinical trial.

In-Person & Online Events

Online Activities

Speakers

Sponsors

Media Partners

Digital Services

Lead Generation Dinners

Content Services

Event Management

Browse All Resources

Filter by Subject Area

Latest Resources

Resources

Top R&D Stories of 2023